ArticleLife (Basel, Switzerland)2022
Clinical Efficacy of an Electronic Portal Imaging Device versus a Physical Phantom Tool for Patient-Specific Quality Assurance.
Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Pre-treatment patient-specific quality assurance (QA) is critical to prevent radiation accidents. The electronic portal imaging device (EPID) is a dose measurement tool with good resolution and a low volume-averaging effect. EPIbeam—an EPID-based portal dosimetry software—has been newly installed in three institutions in Korea. This study evaluated the efficacy of the EPID-based patient-specific QA tool versus the PTW729 detector (a previously used QA tool) based on gamma criteria and planning target volume (PTV). A significant difference was confirmed through the R statistical analysis software. The average gamma passing rates of PTW729 and EPIbeam were 98.73% and 99.60% on 3 mm/3% (local), 96.66% and 97.91% on 2 mm/2% (local), and 88.41% and 74.87% on 1 mm/1% (local), respectively. The p-values between them were 0.015 (3 mm/3%, local), 0.084 (2 mm/2%, local), and less than 0.01 (1 mm/1%, local). Further, the average gamma passing rates of PTW 729 and EPIbeam according to PTV size were 99.55% and 99.91% (PTV < 150 cm3) and 97.91% and 99.28% (PTV > 150 cm3), respectively. The p-values between them were 0.087 (PTV < 150 cm3) and 0.036 (PTV > 150 cm3). These results confirm that EPIbeam can be an effective patient-specific QA tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.